Halozyme prices $1.3B 1.50% convertible notes with $200M option
Halozyme Therapeutics (NASDAQ:HALO) priced $1.3B of 1.50% convertible notes, with an option adding about $200M, raising about $1.275B to fund growth after a record Q2.
Halozyme Therapeutics (NASDAQ:HALO) priced $1.3B of 1.50% convertible notes, with an option adding about $200M, raising about $1.275B to fund growth after a record Q2.